Subtype
Kidney Neoplasm
CI-CAN-00002988Explore in graph →
Non-malignant481 active trials17 approved drugs80 evidence items
Loading cancer entity…
Subtype
CI-CAN-00002988Explore in graph →
Clinical trials
2,320 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00323791 | Gemcitabine With or Without Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Kidney Cancer | terminated | Phase 2 | 100 | University of Medicine and Dentistry of New JerseyOTHER | 1 | Dec 11, 2009 | clinicaltrials |
| NCT00740441 | A Phase II Study of AS1411 in Renal Cell Carcinoma | unknown | Phase 2 | 30 | Antisoma ResearchINDUSTRY | 1 | Sep 25, 2009 | clinicaltrials |
| NCT00389285 | Study of Recombinant Interleukin 21 in Combination With Sorafenib for Metastatic Renal Cell Carcinoma | completed | Phase 1 / Phase 2 | 52 | ZymoGeneticsINDUSTRY | 1 | May 27, 2009 | clinicaltrials |
| NCT00591188 | Capecitabine and Interferon-Alpha in Metastatic Renal Cell Carcinoma Patients With Failure on Interleukin-2 Based Regimens | completed | Phase 2 | 49 | Kidney Cancer Research BureauOTHER | 1 | May 1, 2009 | clinicaltrials |
| NCT00890110 | Autologous Vaccination of Stage 4 Renal Cell Carcinoma Combined With Sunitinib(rcc) | unknown | Phase 1 / Phase 2 | 13 | Hadassah Medical OrganizationOTHER | 0 | Apr 29, 2009 | clinicaltrials |
| NCT00226980 | A Trial of Thalidomide and Capecitabine in Metastatic Renal Cell Carcinoma | completed | Phase 2 | 30 | Stanford UniversityOTHER | 1 | Apr 14, 2009 | clinicaltrials |
| NCT00491738 | A Study Evaluating the Efficacy and Safety of Sunitinib With or Without Bevacizumab in First-Line Patients With Metastatic Renal Cell Cancer (SABRE-R) | terminated | Phase 2 | 16 | Genentech, Inc.INDUSTRY | 0 | Apr 10, 2009 | clinicaltrials |
| NCT00043368 | PF-3512676 (CPG 7909) Injection For Patients Who Completed An Oncology Study Using PF-3512676 (CPG 7909) | completed | Phase 2 | 31 | PfizerINDUSTRY | 2 | Mar 12, 2009 | clinicaltrials |
| NCT00609401 | Study Comparing Association Between Sorafenib and Interleukin-2 (IL-2) Versus Sorafenib in 1st Line Therapy in Advanced (Adv) Renal Cell Carcinoma (RCC)(ROSORC) | completed | Phase 2 | 90 | Italian Trial in Medical OncologyOTHER | 1 | Feb 26, 2009 | clinicaltrials |
| NCT00043407 | CPG 7909 in Patients Wih Stage IV Renal Cell Cancer | completed | Phase 1 / Phase 2 | 42 | PfizerINDUSTRY | 0 | Feb 12, 2009 | clinicaltrials |
| NCT00496301 | Clinical Trial on the Mixture of G, C and S in Treatment of Patients With RCC(SOGUG-02-06) | completed | Phase 2 | 40 | Spanish Oncology Genito-Urinary GroupOTHER | 1 | Jan 14, 2009 | clinicaltrials |
| NCT00425204 | Study for Patients Who Have Benefited and Tolerated Prior Panitumumab Treatment | completed | Phase 2 | 31 | AmgenINDUSTRY | 0 | Sep 15, 2008 | clinicaltrials |
| NCT00024388 | Chemotherapy in Treating Patients With Metastatic Kidney Cancer | unknown | Phase 2 | — | TheradexINDUSTRY | 1 | Jul 24, 2008 | clinicaltrials |
| NCT00039169 | BAY 59-8862 in Treating Patients With Advanced Kidney Cancer | unknown | Phase 2 | — | TheradexINDUSTRY | 2 | Jul 24, 2008 | clinicaltrials |
| NCT00422786 | Phase II Study of CAP-232 in Patients With Refractory Metastatic Renal Cell Carcinoma | completed | Phase 2 | 10 | Thallion PharmaceuticalsINDUSTRY | 1 | Jul 15, 2008 | clinicaltrials |
| NCT00095186 | Safety/Efficacy Study of Oral Recombinant Human Lactoferrin in Renal Cell Carcinoma | completed | Phase 2 | 40 | AgennixINDUSTRY | 1 | Apr 10, 2008 | clinicaltrials |
| NCT00059735 | A Safety, Tolerability and Efficacy Study of E7070 in Patients With Renal Cell Carcinoma | completed | Phase 2 | 30 | Eisai Inc.INDUSTRY | 2 | Mar 5, 2008 | clinicaltrials |
| NCT00056173 | Combination of Capecitabine and GTI-2040 in the Treatment of Renal Cell Carcinoma | completed | Phase 1 / Phase 2 | 43 | Aptose Biosciences Inc.INDUSTRY | 1 | Jan 7, 2008 | clinicaltrials |
| NCT00417677 | A Study Combining Treatment With Temsirolimus and Sunitinib for Subjects With Advanced Renal Cell Carcinoma | terminated | Phase 1 / Phase 2 | 124 | Wyeth is now a wholly owned subsidiary of PfizerINDUSTRY | 1 | Dec 28, 2007 | clinicaltrials |
| NCT00131651 | ATN-161 in Advanced Renal Cell Cancer | terminated | Phase 2 | 36 | AttenuonINDUSTRY | 1 | Dec 6, 2007 | clinicaltrials |
| NCT00073112 | A Study of ABT-751 in Patients With Renal Cell Cancer | completed | Phase 2 | 60 | AbbottINDUSTRY | 2 | Nov 29, 2007 | clinicaltrials |
| NCT00073125 | Safety and Efficacy of ABT-510 in Subjects With Advanced Renal Cell Carcinoma | completed | Phase 2 | 103 | AbbottINDUSTRY | 2 | Aug 15, 2007 | clinicaltrials |
| NCT00054886 | Study of the Safety and Efficacy of SU-011,248 in Adult Patients With Advanced Kidney Cancer | completed | Phase 2 | 63 | PfizerINDUSTRY | 1 | May 7, 2007 | clinicaltrials |
| NCT00134186 | Study of Motexafin Gadolinium for the Treatment of Renal Cell (Kidney) Cancer | completed | Phase 2 | 43 | Pharmacyclics LLC.INDUSTRY | 1 | Mar 5, 2007 | clinicaltrials |
| NCT00151645 | Efficacy of Activated Lymphocytes in Renal Cell Carcinoma. | terminated | Phase 2 | 36 | Rennes University HospitalOTHER | 1 | Jan 2, 2006 | clinicaltrials |
Data updated 22 days agoSource updated Dec 11, 2009source: clinicaltrials